Maze Therapeutics insider grant: 25,000 RSUs to CSBO Dandekar

Rhea-AI Filing Summary

Maze Therapeutics insider award: Atul Dandekar, listed as CSBO and officer, was granted 25,000 restricted stock units (RSUs) on 09/22/2025. Each RSU represents a contingent right to one share of Maze Therapeutics common stock upon settlement. The award vests in two equal installments: 12,500 RSUs on September 1, 2026 and 12,500 RSUs on September 1, 2027, subject to the reporting persons continued service on each vesting date. The RSUs do not expire and will either vest or be cancelled prior to the vesting dates. After the grant, the reporting person beneficially owns 25,000 shares (directly) from this award. The Form 4 was signed by an attorney-in-fact on 09/24/2025.

Positive

• 25,000 RSUs granted to reporting person (Atul Dandekar) documented on 09/22/2025
• Clear vesting schedule: 12,500 RSUs vest on 09/01/2026 and 12,500 RSUs vest on 09/01/2027
• Each RSU converts to one share on settlement; award does not expire

Negative

• None.

Insights

Securities Analyst

TL;DR: A routine officer equity award: 25,000 RSUs granted with two-year staggered vesting; disclosure is standard Section 16 reporting.

The filing documents a non-derivative equity award granted to Atul Dandekar, Maze Therapeutics CSBO, consisting of 25,000 restricted stock units that convert one-for-one into common shares upon settlement. Vesting occurs in two equal tranches on September 1, 2026 and September 1, 2027, conditional on continued service. The RSUs are reported as directly beneficially owned following the transaction. This disclosure complies with Section 16 timing and signature requirements and contains no explicit performance conditions or exercise price.

Corporate Governance Expert

TL;DR: Standard executive compensation disclosure; timing and vesting terms are clearly stated and unremarkable.

The Form 4 provides clear descriptions of the award mechanics: each RSU equals one share at settlement, the award vests 50% after one year and the remaining 50% after two years, and RSUs do not carry an expiration date. The filing is signed by an authorized attorney-in-fact, indicating procedural completion. No additional governance concerns such as change-in-control accelerations or amendatory provisions are disclosed in this document.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Dandekar Atul

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CSBO

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	09/22/2025		A		25,000		(2)	(3)	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

2. The award shall vest as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date.

3. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Atul Dandekar report on the Form 4 for MAZE?

The Form 4 reports a grant of 25,000 restricted stock units (RSUs) to Atul Dandekar, an officer (CSBO) of Maze Therapeutics, dated 09/22/2025.

When do the 25,000 RSUs vest for MAZE insider Atul Dandekar?

The RSUs vest in two equal tranches: 12,500 on September 1, 2026 and 12,500 on September 1, 2027, subject to continued service.

How many shares does each RSU represent in the MAZE Form 4?

Each restricted stock unit represents a contingent right to receive one share of Maze Therapeutics common stock upon settlement.

Does the award reported in the MAZE Form 4 expire?

According to the filing, these restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

How many shares does the reporting person beneficially own after the transaction?

The Form 4 shows the reporting person beneficially owns 25,000 shares following the reported transaction.